Samir H. Barghout

Samir H. Barghout

Auto-generated profile, based on publicly available information

Samir H. Barghout

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Cancer Cell
Verified
Journal Article
Closed access
JIJo Ishizawa
Jo Ishizawa
SZSarah F. Zarabi
Sarah F. Zarabi
RDR. Eric Davis
R. Eric Davis
OHOndrej Halgas
Ondrej Halgas
TNTakenobu Nii
Takenobu Nii
MAMichael Andreeff
Michael Andreeff

1 January 2021 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
SBSamir H Barghout
Samir H Barghout
ASAaron Schimmer
Aaron Schimmer
Post-translational modifications of cellular substrates with ubiquitin and ubiquitin-like proteins (UBLs), including ubiquitin, SUMOs, and neural precursor cell–expressed developmentally downregulated protein 8, play a central role in regulating many aspects of cell biology. The UBL conjugation cascade is initiated by a family of ATP-dependent enzymes termed E1 activating enzymes and executed by the downstream E2-conjugating enzymes and E3 ligases. Despite their druggability and their key position at the apex of the cascade, pharmacologic modulation of E1s with potent and selective drugs has remained elusive until 2009. Among the eight E1 enzymes identified so far, those initiating ubiquitylation (UBA1), SUMOylation (SAE), and neddylation (NAE) are the most characterized and are implicated in various aspects of cancer biology. To date, over 40 inhibitors have been reported to target UBA1, SAE, and NAE, including the NAE inhibitor pevonedistat, evaluated in more than 30 clinical trials. In this Review, we discuss E1 enzymes, the rationale for their therapeutic targeting in cancer, and their different inhibitors, with emphasis on the pharmacologic properties of adenosine sulfamates and their unique mechanism of action, termed substrate-assisted inhibition. Moreover, we highlight other less-characterized E1s—UBA6, UBA7, UBA4, UBA5, and autophagy-related protein 7—and the opportunities for targeting these enzymes in cancer. Significance Statement The clinical successes of proteasome inhibitors in cancer therapy and the emerging resistance to these agents have prompted the exploration of other signaling nodes in the ubiquitin-proteasome system including E1 enzymes. Therefore, it is crucial to understand the biology of different E1 enzymes, their roles in cancer, and how to translate this knowledge into novel therapeutic strategies with potential implications in cancer treatment.

8 June 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
SBSamir H. Barghout
Samir H. Barghout
PPParasvi S. Patel
Parasvi S. Patel
XWXiaoming Wang
Xiaoming Wang
GXG. Wei Xu
G. Wei Xu
SKSimon Kavanagh
Simon Kavanagh
ASAaron Schimmer
Aaron Schimmer

11 February 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SMSafa Majeed
Safa Majeed
MAMansi K. Aparnathi
Mansi K. Aparnathi
KNKevin CJ Nixon
Kevin CJ Nixon
VVVidhyasagar Venkatasubramanian
Vidhyasagar Venkatasubramanian
FRFariha Rahman
Fariha Rahman
BLBenjamin H Lok
Benjamin H Lok
Purpose: Small cell lung cancer (SCLC) is an aggressive disease with an overall 5-year survival rate of less than 10%. Treatment for SCLC with cisplatin/etoposide chemotherapy (C/E) ± radiotherapy has changed modestly over several decades. The ubiquitin-proteasome system is an underexplored therapeutic target for SCLC. We preclinically evaluated TAK-243, a first-in-class small molecule E1 inhibitor against UBA1. Experimental Design: We assessed TAK-243 in 26 SCLC cell-lines as monotherapy and combined with C/E, the PARP-inhibitor, olaparib, and with radiation using cell viability assays. We interrogated TAK-243 response with gene expression to identify candidate biomarkers. We evaluated TAK-243 alone and in combination with olaparib or radiotherapy with SCLC patient-derived xenografts (PDX). Results: Most SCLC cell lines were sensitive to TAK-243 monotherapy (EC50 median 15.8 nmol/L; range 10.2 nmol/L–367.3 nmol/L). TAK-243 sensitivity was associated with gene-sets involving the cell cycle, DNA and chromatin organization, and DNA damage repair, while resistance associated with cellular respiration, translation, and neurodevelopment. These associations were also observed in SCLC PDXs. TAK-243 synergized with C/E and olaparib in vitro across sensitive and resistant SCLC cell lines. Considerable TAK-243–olaparib synergy was observed in an SCLC PDX resistant to both drugs individually. TAK-243 radiosensitization was also observed in an SCLC PDX. Conclusions: TAK-243 displays efficacy in SCLC preclinical models. Enrichment of gene sets is associated with TAK-243 sensitivity and resistance. TAK-243 exhibits synergy when combined with genotoxic therapies in cell lines and PDXs. TAK-243 is a potential therapeutic strategy to improve SCLC patient outcomes, both as a single agent and in combination with existing therapies.

1 December 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SBSamir H. Barghout
Samir H. Barghout
NZNubia Zepeda
Nubia Zepeda
ZXZhihua Xu
Zhihua Xu
HSHelen Steed
Helen Steed
CLCheng-Han Lee
Cheng-Han Lee
YFYangXin Fu
YangXin Fu

8 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
SBSamir H. Barghout
Samir H. Barghout
AAAhmed Aman
Ahmed Aman
KNKazem Nouri
Kazem Nouri
ZBZachary Blatman
Zachary Blatman
KAKaren Arevalo
Karen Arevalo
ASAaron Schimmer
Aaron Schimmer
TAK-243 is a first-in-class inhibitor of ubiquitin-like modifier activating enzyme 1 that catalyzes ubiquitin activation, the first step in the ubiquitylation cascade. Based on its preclinical efficacy and tolerability, TAK-243 has been advanced to phase I clinical trials in advanced malignancies. Nonetheless, the determinants of TAK-243 sensitivity remain largely unknown. Here, we conducted a genome-wide CRISPR/Cas9 knockout screen in acute myeloid leukemia (AML) cells in the presence of TAK-243 to identify genes essential for TAK-243 action. We identified BEN domain-containing protein 3 ( BEND3 ), a transcriptional repressor and a regulator of chromatin organization, as the top gene whose knockout confers resistance to TAK-243 in vitro and in vivo. Knockout of BEND3 dampened TAK-243 effects on ubiquitylation, proteotoxic stress, and DNA damage response. BEND3 knockout upregulated the ATP-binding cassette efflux transporter breast cancer resistance protein (BCRP; ABCG2) and reduced the intracellular levelsof TAK-243. TAK-243 sensitivity correlated with BCRP expression in cancer cell lines of different origins. Moreover, chemical inhibition and genetic knockdown of BCRP sensitized intrinsically resistant high-BCRP cells to TAK-243. Thus, our data demonstrate that BEND3 regulates the expression of BCRP for which TAK-243 is a substrate. Moreover, BCRP expression could serve as a predictor of TAK-243 sensitivity.